Search results
Results from the WOW.Com Content Network
HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.
Antiretroviral treatment among people with HIV whose CD4 count ≤ 550 cells/μL is a very effective way to prevent HIV infection of their partner (a strategy known as treatment as prevention, or TASP). [136] TASP is associated with a 10- to 20-fold reduction in transmission risk.
In the past there have been cases of HIV transmission to an HIV-negative partner through processed artificial insemination, [121] but a large modern series in which followed 741 couples where the man had a stable viral load and semen samples were tested for HIV-1, there were no cases of HIV transmission. [122]
New forms of pre-exposure prophylaxis, or PrEP, could be used by groups who find daily preventive medications too burdensome.
In Columbus, Ohio, a teenage boy who was undergoing treatment for substance use disorder was surprised a couple years ago to learn he'd been infected with hepatitis C. The boy, then 17, was ...
There has been some evidence that other regimens, like ones based on the antiretroviral agent Maraviroc, could potentially prevent HIV infection. [102] Similarly, researchers are investigating whether drugs could be used in ways other than a daily pill to prevent HIV, including PrEP-releasing implants or rectally administered PrEP. [103]
Transmission-based precautions are infection-control precautions in health care, in addition to the so-called "standard precautions". They are the latest routine infection prevention and control practices applied for patients who are known or suspected to be infected or colonized with infectious agents, including certain epidemiologically important pathogens, which require additional control ...
The trial, CAPRISA 004, was conducted among 889 women to evaluate the ability of 1% tenofovir gel to prevent male-to-female HIV transmission. The study found a 39% lower HIV infection rate in women using 1% tenofovir gel compared with women using a placebo gel. In addition, tenofovir gel was shown to be safe as tested. [21]